Blog

An amazing 2015.

Our sixth year was TargetCancer Foundation’s best ever, as we saw unprecedented growth and research success. We are gearing up for an even bigger 2016, but in the meantime, here’s a look back at at some of our accomplishments from the last year. Continue reading

A Mother’s Love

This is the first in a series of profiles highlighting the stories of those fighting rare cancers, as well as their friends and family. This series was initiated by TargetCancer Foundation intern Alexa Parisi, who has also written the inaugural post below.  Continue reading

A forum to tell your rare cancer story.

Everyone facing a rare cancer has a story to tell. Whether you are the patient, the doctor, the caregiver, the survivor, or the friend or family member, your story is important, and deserves to be heard by others. Continue reading

Team TargetCancer Foundation returns to the Boston Marathon in 2016!

In 2015, TargetCancer Foundation was proud to participate in the Boston Marathon for the first time, and it was a major success. Not only did our inaugural runners Nicole Garceau and Alex Reid finish their first marathons, they combined to raise over $35,000- an amazing fundraising feat that had an immediate impact on our rare cancer research initiatives.

Today, we are proud to announce that Team TargetCancer Foundation will be returning to the Boston Marathon in 2016! On April 18, 2016, a team of three runners will begin their journey in Hopkinton, MA before running 26.2 miles to the finish on Boylston Street. We are thrilled to have this opportunity to participate again, and grateful to the John Hancock Non-Profit Marathon Program for awarding these numbers to us.

 

Fostering esophageal cancer progress.

In 2012, we identified a need for a scientific meeting uniting key players in cholangiocarcinoma research. In order to best foster collaboration and informal discussion, however, we wanted a format that was different that that of the typical scientific meeting. This approach led us to the TargetCancer Foundation Think Tank on Cholangiocarcinoma– a unique meeting that united not only cholangiocarcinoma experts, but also leaders from other rare cancers who shared their experiences of successfully bringing those cancers out of orphan status. Continue reading

The TargetCancer Foundation Gala moves to Fenway Park!

The baseball season will be over, but on November 19th we’ll be at Fenway Park raising funds for rare cancer research at A Night to TargetCancer: The 6th Annual TargetCancer Foundation Gala!

Join us there and see Fenway set up with an endzone in the outfield in advance of the historic game between Boston College and Notre Dame.

Tickets are on sale now! Learn more at our 2015 Gala page.

Casual beginnings for an innovative collaboration.

Great coverage of TargetCancer Foundation’s support of an innovative esophageal cancer collaboration at the Dana-Farber Cancer Institute. Continue reading

Golfing for hope.

UPDATE:  The Matt Lindsay Memorial Golf Tournament was a major success! 16 teams and 64 golfers came out on a beautiful day to honor the memory of Matt Lindsay, and raise critical funds for cholangiocarcinoma research. Over $19,000 was raised, and the funds will be put to use almost immediately in support of TargetCancer Foundation’s cholangiocarcinoma research programs at the Massachusetts General Hospital Cancer Center. 

Continue reading

Giving new hope to patients.

When the late Paul Poth was diagnosed with a form of cancer so rare there was no treatment, he helped to launch a highly promising area of cancer research that is giving new hope to patients.” 

A great piece from a Massachusetts General Hospital newsletter on TargetCancer Foundation’s work with MGH that recently led to a new cholangiocarcinoma clinical trial.

Read the entire story here.

You can help support this clinical trial! Learn more.

Help us reach our clinical trial goal!

We recently announced the exciting news that research initiated by TargetCancer Foundation has led to a new cholangiocarcinoma clinical trial. We are truly proud to have been a part of the process leading to this trial, and now we’re just as excited to provide funding to support the trial itself. Continue reading